DoW Toxic Exposures Clinical Trial Award
Funds clinical trials that test prevention, treatment, or symptom management interventions for conditions associated with military-related toxic exposures, including pilot through large efficacy trials, for eligible applicants that may include partnering investigators.
⚑ Partnering Principal Investigator Option (PPIO) allows two PIs on separate awards if funded. · Clinical trial award; projects must include an actual clinical trial, not just preclinical or observational work. · Focus is military-related toxic exposures under TERP. · No cost-sharing mentioned in the notice.
Unit fits — one characterization, each unit's own rules
| Physical Sciences & Engineering (demo) | 65 good | technical depth: minor; funds applied research |
| IPPRA | 58 good | portfolio topics: public_health, environment; signature methods: community engaged; social/behavioral work is minor; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Tom Love Innovation Hub | 30 weak | funds applied research; deep-tech content |
Description
Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations.
Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO) . One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts.
https://cdmrp.health.mil/pubs/press/2026/terppreann
Apply
View on Grants.gov → CONTACT: Ebony S Simmons Grantor <help@eBRAP.org>
Proposal brief SEE AN EXAMPLE →
A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.
Proposal shell · Department of Defense (BAA-style) conventions SEE A DOD EXAMPLE →
Funder-faithful document skeletons — Department of Defense (BAA-style)'s document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.